Major depression affects millions of adults in the United States, and women are affected at twice the rate of men. Approximately 30% of individuals may continue to experience depression symptoms despite treatment with oral antidepressants. In March 2019, the U.S. Food and Drug Administration approved esketamine (Spravato), which is specifically indicated for treatment-resistant depression. Available as a nasal spray in a health care office or facility, esketamine has the potential to fill an unmet need for individuals who continue to experience depression with conventional treatment. Symptom improvement may be seen as rapidly as 1 week after treatment initiation. This article provides an overview of esketamine, including administration, adverse effects, and practice implications for women's health nurses.
Keywords: Spravato; depression; depression disorder; esketamine; nasal spray.
Copyright © 2020. Published by Elsevier Inc.